Currency In USD
| Previous Close | 1.67 |
| Open | 1.72 |
| Day High | 1.73 |
| Day Low | 1.62 |
| 52-Week High | 4.94 |
| 52-Week Low | 1.62 |
| Volume | 825,072.71 |
| Average Volume | 1.33M |
| Market Cap | 93.69M |
| PE | -2.12 |
| EPS | -0.77 |
| Moving Average 50 Days | 2.56 |
| Moving Average 200 Days | 2.89 |
| Change | -0.04 |
Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM
GlobeNewswire Inc.
Dec 03, 2025 12:01 PM GMT
Silevertinib delivers robust anti-tumor activity as demonstrated by an ORR of 60% and a CNS response rate of 86% in 43 1L NSCLC patients presenting with 35 different non-classical EGFR mutations; no new safety signals observed to datePFS data for 1L
Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update
GlobeNewswire Inc.
Dec 02, 2025 9:01 PM GMT
Webcast to be held Wednesday, December 3, at 8:00am ET CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of onc
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
GlobeNewswire Inc.
May 29, 2025 12:00 PM GMT
CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announce